pubs.acs.org/acsmedchemlett
M. M.; Lawrence, N. J.; Sebti, S. M.; Turkson, J. Selective
chemical probe inhibitor of Stat3, identified through struc-
ture-based virtual screening, induces antitumor activity. Proc.
Natl. Acad. Sci. U.S.A. 2007, 104, 7391–7396.
Siddiquee, K. A. Z.; Gunning, P. T.; Glenn, M.; Katt, W. P.;
Zhang, S.; Schroeck, C.; Sebti, S. M.; Jove, R.; Hamilton,
A. D.; Turkson, J. An Oxazole-Based Small-Molecule Stat3
Inhibitor Modulates Stat3 Stability and Processing and
Induces Antitumor Cell Effects. ACS Chem. Biol. 2007, 2,
787–798.
of transcription 3 (Stat3) protein. ChemMedChem 2008, 3,
1159–1168.
(23) Fletcher, S.; Shahani, V. M.; Gunning, P. T. Facile and efficient
access to 2,6,9-tri-substituted purines through sequential N9,
N2 Mitsunobu reactions. Tetrahedron Lett. 2009, 50 (29),
4258–4261.
(8)
(9)
(24) Fletcher, S.; Shahani, V. M.; Lough, A. J.; Gunning, P. T.
Tetrahedron 2010, DOI: 10.1016/j.tet.2010.03.118.
(25) Turkson, J.; Zhang, S.; Mora, L. B.; Burns, A.; Sebti, S.; Jove, R.
A novel platinum compound inhibits constitutive Stat3 sig-
naling and induces cell cycle arrest and apoptosis of malig-
nant cells. J. Biol. Chem. 2005, 280, 32979–32988.
(26) Coleman, D. R.; Ren, Z.; Mandal, P. K.; Cameron, A. G.; Dyer,
G. A.; Muranjan, S.; Campbell, M.; Chen, X.; McMurray, J. S.
Investigation of the binding determinants of phosphopep-
tides targeted to the SRC homology 2 domain of the signal
transducer and activator of transcription 3. Development of a
high-affinity peptide inhibitor. J. Med. Chem. 2005, 48, 6661–
6670.
(27) Mandal, P. K.; Limbrick, D.; Coleman, D. R.; Dyer, G. A.; Ren,
Z.; Birtwistle, J. S.; Xiong, C.; Chen, X.; Briggs, J. M.; McMurray,
J. S. Conformationally constrained peptidomimetic inhibitors
ofsignaltransducerand activatoroftranscription3:evaluation
and molecular modeling. J. Med. Chem. 2009, 52, 2429–2442.
(28) Galmarini, C. M.; Mackey, J. R.; Dumontet, C. Nucleoside
analogues and nucleobases in cancer treatment. Lancet
Oncol. 2002, 3, 415–424.
Chen, J.; Bai, L.; Bernard, D.; Nikolovska-Coleska, Z.; Gomez,
C.; Zhang, J.; Yi, H.; Wang, S. Structure-Based Design of
Conformationally Constrained, Cell-Permeable STAT3 Inhibi-
tors. ACS Med. Chem. Lett. 2010, 1, 85–89.
(10) Lin, L.; Hutzen, B.; Zuo, M.; Ball, S.; Deangelis, S.; Foust, E.;
Pandit, B.; Ihnat, M. A.; Shenoy, S. S.; Kulp, S.; Li, P. K.; Li, C.;
Fuchs, J.; Lin, J. Novel STAT3 phosphorylation inhibitors
exhibit potent growth-suppressive activity in pancreatic and
breast cancer cells. Cancer Res. 2010, 70, 2445–2454.
(11) Bhasin, D.; Cisek, K.; Pandharkar, T.; Regan, N.; Li, C.; Pandit,
B.; Lin, J.; Li, P. K. Design, synthesis, and studies of small
molecule STAT3 inhibitors. Bioorg. Med. Chem. Lett. 2008, 18,
391–395.
(12) Song, H.; Wang, R.; Wang, S.; Lin, J. A low-molecular-weight
compound discovered through virtual database screening
inhibits Stat3 function in breast cancer cells. Proc. Natl. Acad.
Sci. U.S.A. 2005, 102, 4700–4705.
(29) Parker, W. B.; Secrist, J. A., 3rd; Waud, W. R. Purine nucleoside
antimetabolites in development for the treatment of cancer.
Curr. Opin. Invest. Drugs 2004, 5, 592–596.
(13) Schust, J.; Sperl, B.; Hollis, A.; Mayer, T. U.; Berg, T. Stattic: a
small-molecule inhibitor of STAT3 activation and dimeriza-
tion. Chem. Biol. 2006, 13, 1235–1242.
(14) Ren, Z.; Cabell, L. A.; Schaefer, T. S.; McMurray, J. S. Identi-
fication of a high-affinity phosphopeptide inhibitor of stat3.
Bioorg. Med. Chem. Lett. 2003, 13, 633–636.
(15) McMurray, J. S.; Mandal, P. K.; Liao, W. S.; Ren, Z.; Chen, X.
Inhibition of Stat3 by cell-permeable peptidomimetic pro-
drugs targeted to its SH2 domain. Adv. Exp. Med. Biol. 2009,
611, 545–546.
(16) Zhang, X.; Yue, P.; Fletcher, S.; Zhao, W.; Gunning, P. T.;
Turkson, J. A novel small-molecule disrupts Stat3 SH2
domain-phosphotyrosine interactions and Stat3-dependent
tumor processes. Biochem. Pharmacol. 2010, 79, 1398–1409.
(17) Gunning, P. T.; Glenn, M. P.; Siddiquee, K. A.; Katt, W. P.;
Masson, E.; Sebti, S. M.; Turkson, J.; Hamilton, A. D. Targeting
protein-protein interactions: suppression of Stat3 dimeriza-
tion with rationally designed small-molecule, nonpeptidic
SH2 domain binders. ChemBioChem 2008, 9, 2800–2803.
(18) Gunning, P. T.; Katt, W. P.; Glenn, M.; Siddiquee, K.; Kim, J. S.;
Jove, R.; Sebti, S. M.; Turkson, J.; Hamilton, A. D. Isoform
selective inhibition of STAT1 or STAT3 homo-dimerization via
peptidomimetic probes: structural recognition of STAT SH2
domains. Bioorg. Med. Chem. Lett. 2007, 17, 1875–1878.
(19) Turkson, J.; Zhang, S.; Palmer, J.; Kay, H.; Stanko, J.; Mora,
L. B.; Sebti, S.; Yu, H.; Jove, R. Inhibition of constitutive signal
transducer and activator of transcription 3 activation by
novel platinum complexes with potent anti-tumor activity.
Mol. Cancer Ther. 2004, 3, 1533–1542.
(20) Becker, S.; Groner, B.; Muller, C. W. Three-dimensional struc-
ture of the Stat3beta homodimer bound to DNA. Nature
1998, 394, 145–151.
(21) Jones, G.; Willett, P.; Glen, R. C.; Leach, A. R.; Taylor, R.
Development and validation of a genetic algorithm for flex-
ible docking. J. Mol. Biol. 1997, 267, 727–748.
(22) Fletcher, S.; Turkson, J.; Gunning, P. T. Molecular approaches
towards the inhibition of the signal transducer and activator
r
2010 American Chemical Society
84
DOI: 10.1021/ml100224d ACS Med. Chem. Lett. 2011, 2, 79–84
|